BioRestorative Therapies (BRTX) investor relations material

Executive summary

• Achieved strong execution across all business areas in Q2 2025, with revenue of $303,000–$303,300, up 240% year-over-year, driven by contract manufacturing and BioCosmeceutical sales.

• Net loss for Q2 2025 was $2.7 million ($0.30/share), improved from $4.0–$4.03 million ($0.50/share) in Q2 2024.

• Research and development expenses increased due to expanded clinical trial activity and lab supply costs.

• Advanced commercial opportunities in regenerative biologic secretome products, contract manufacturing, and new cosmetic product business.

• Focused on Disc/Spine Program (BRTX-100), ThermoStem Program, and strategic growth initiatives.

Financial highlights

• Q2 2025 revenues reached $303,000–$303,300, up 240% year-over-year, with gross profit of $294,571.

• Loss from operations was $3.3 million, compared to $2.5 million in Q2 2024.

• Net loss per share improved to $0.30 from $0.50 year-over-year.

• Ended Q2 2025 with $7.4 million in cash, cash equivalents, and marketable securities, and no debt.

• Working capital was $3.93 million as of June 30, 2025.

Outlook and guidance

• Optimistic about continued enrollment and positive data trends in the BRTX-100 phase 2 trial.

• Expecting further regulatory engagement with the FDA, including a Type B meeting to accelerate BLA pathway.

• Management expects continued net losses and negative cash flows as development and clinical activities progress.

• Current funds are insufficient for long-term operations, raising substantial doubt about the ability to continue as a going concern without additional financing.

• SG&A expenses expected to follow a similar pattern as last year, with higher Q1 and lighter subsequent quarters.